RESEARCH AND INNOVATION

Concept Foundation’s Research and Innovation team identifies, develops and evaluates new and neglected high potential sexual and reproductive health (SRH) medicines and technologies.

We scan and review the field to identify SRH products that are likely to be safe and effective and in parallel reduce inequities in our efforts to achieve Universal Health Coverage.

Photo Credit: Joni Kabana

rESEARCH AND INNOVATION

Concept Foundation’s Research and Innovation team identifies, develops and evaluates new and neglected high potential sexual and reproductive health (SRH) medicines and technologies.

We scan and review the field to identify SRH products that are likely to be safe and effective and in parallel reduce inequities in our efforts to achieve Universal Health Coverage.

Photo Credit: Joni Kabana

Basic and clinical research

  • We evaluate the benefits and harms of existing and new interventions
  • We develop new interventions for which there is a market need
    • New treatments
    • Diagnostics
    • Point-of-care tests
  • We use modern technologies to improve drug stability

Innovation

  • We perform landscape analysis of pipeline and marketed products
    • Contraception
    • Safe Medical Abortion
    • Maternal Health
  • We identify gaps in treatment options and other needs in maternal and reproductive health
  • We search for, and evaluate, new promising innovations

For questions and collaborations, please contact the R&D Programme Manager

OUR RESEARCH APPROACH

Concept Foundation is mandated to work on quality-assured reproductive health medicines and technologies.

 

Between 2010 and 2020, CF conducted quality assessments of a large range of essential reproductive health medicines through our work within the Quality of Reproductive Health Medicines Programme (QuRHM) and the UN Commission for Life Saving Commodities. We continue to work on field collection of medicines and conduct testing with our partner laboratories.

Our second approach is to identify new and existing but inadequately evaluated and partly forgotten medicines. We believe that there should be more research and innovation to develop solutions for pregnancy-specific conditions like pre-eclampsia/eclampsia, preterm labour and birth, and obstetric haemorrhage. Similarly, we are working to improve contraceptive and pregnancy termination options through innovative approaches.

We are working on exploring and potentially expanding self-care for sexual and reproductive health medicines and technologies by conducting landscaping and systematic reviews. Our research approach is collaborative. We work closely with HRP/WHO, Birmingham University, UK, Monash University Institute of Pharmaceutical Sciences and the Burnet Institute, Australia and other partner organizations globally.